Drug Discovery & Development
Could heparin-based therapies be a viable treatment for COVID-19?
Researchers have identified a novel approach to treating SARS-CoV-2 infection, spurred by a new understanding of viral attachment involving a heparan sulfate, a common glycoprotein. The results are presented in a September 14 article published in Cell.  Discuss
Antibody fragments may be exceptionally effective against SARS-CoV-2
An engineered antibody fragment has been developed as a highly potent neutralizer of SARS-CoV-2. For the first time, one of these tiny molecules has been tested for efficacy in in vitro and in vivo infection models. The results of the collaborative study were published in Cell on September 14.  Discuss
Optofluidics technology accelerates discovery of COVID-19 treatments
Known for its transformative technology, Berkeley Lights is a pioneer in optofluidics, which has supported the biopharmaceutical industry for years with its deep cell characterization capabilities. These efforts are highlighted by the rapid impact that Berkeley Lights' Beacon systems had during the early days of the COVID-19 pandemic.  Discuss
New approach to cancer immunotherapies combines 2 mAb treatments
A new approach to increasing the effectiveness of current cancer immunotherapies combines existing therapies with new monoclonal antibodies (mAb) that block inhibitory cytokines in tumor microenvironments, allowing the body to effectively eliminate tumors. The results of the study were published in Nature Communications on September 11.  Discuss
New technique reins in inflammatory response of adjuvants
Adjuvants are often added to vaccines as a method for promoting an immune response in recipients. But what happens when that immune response goes haywire, causing too much inflammation? Researchers believe that adding an "immune potentiator" to adjuvants that strengthens the immune reaction and modulates excess inflammation could lead to vaccines that are better tolerated in humans, according to a September 9 article in Science Advances.  Discuss
New CRISPR-repressor system improves efficiency of gene therapies
Researchers have developed a CRISPR-based system that can simultaneously provide transcriptional control and gene editing on demand to improve the efficacy of gene therapies. The details were published in Nature Cell Biology on September 3.  Discuss
Protein engineering creates highly potent experimental SARS-CoV-2 vaccine
A bioengineering technique that utilizes various naturally occurring sequences and de novo design of messenger RNA (mRNA) components was applied to develop an mRNA-based vaccine that could be highly effective against SARS-CoV-2, according to a new article published in Advanced Materials on September 2.  Discuss
New small-molecule drug targets hard-to-reach cancer-linked enzyme
Researchers have developed a new class of small-molecule drugs that show promise against a subset of pediatric leukemia with the NUP98-NSD1 chromosomal translocation. The findings were published in Nature Chemical Biology on August 31.  Discuss
ESMO recommends use of NGS for advanced cancers
The European Society for Medical Oncology (ESMO) released its first recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers. The guidance was published in the Annals of Oncology on August 25.  Discuss
SARS-CoV-2 spike protein hinges like leg joints to seek receptors
New research demonstrates that the SARS-CoV-2 spike protein may be more flexible than previously thought, with hinges similar to leg joints to seek receptors on a host, according to a new article published in Science on August 18. Understanding molecular dynamics of how the spike protein functions could have implications in therapeutic and vaccine design.  Discuss
Conferences
ESMO Virtual Congress 2020
September 14-29
Online
2020 ACCP Annual Meeting
September 20-22
Online
BioProcess International West
September 21-25
Online
BioProcess International
September 21-25
Online
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter